Presentation is loading. Please wait.

Presentation is loading. Please wait.

AFR Measles-Rubella TAG Meeting, 2015 1 |1 | The Performance of the Regional Laboratory Network Nairobi, 2-3 June 2015 The Performance of the Regional.

Published byHoward Day Modified over 9 years ago

Similar presentations

Presentation on theme: "AFR Measles-Rubella TAG Meeting, 2015 1 |1 | The Performance of the Regional Laboratory Network Nairobi, 2-3 June 2015 The Performance of the Regional."— Presentation transcript:

1 AFR Measles-Rubella TAG Meeting, 2015 1 |1 | The Performance of the Regional Laboratory Network Nairobi, 2-3 June 2015 The Performance of the Regional Laboratory Network Nairobi, 2-3 June 2015 AFR Measles-Rubella TAG Meeting

2 AFR Measles-Rubella TAG Meeting, 2015 2 |2 | Outline  Distribution of measles laboratories in AFR Region  Performance indicators  Measles genotypes  Main Challenges  Way forward  Question for TAG members

3 AFR Measles-Rubella TAG Meeting, 2015 3 |3 | Distribution of Measles Rubella Lab. National Lab Sub National Lab Regional Ref. Lab  N=47 labs  One lab/country except NIE (4) & ETH (3)  No lab: EQG, STP, CAV, SEY, MAS  Funding: MR initiative

4 AFR Measles-Rubella TAG Meeting, 2015 4 |4 | Distribution of Measles Rubella Lab. Network (cn’t)  Coordination at IST level -1 lab person: IST ESA -1 lab person: ISTs CA/WA  Diagnostic capacities -Serology: all labs -Virus isolation/PCR: selected labs -Sequencing: 3 RRLs

5 AFR Measles-Rubella TAG Meeting, 2015 5 |5 | Main Lab. Network Activities  Standardization: equipments (purchased by WHO), technique, kits, testing algorithm, lab database  External quality control system in place  Regular trainings (bench work & data management) organized  Monitoring of performance indicators  Accreditation review & lab director meeting  WHO support: kits, basic supplies, funds for operationnal cost

6 AFR Measles-Rubella TAG Meeting, 2015 6 |6 | Main Lab. Performance Indicators

7 AFR Measles-Rubella TAG Meeting, 2015 7 |7 | Timeliness & Completeness in Sharing Database Few labs have met the expected target (>=80%) due to internet connexion challenges, conflicting priority activities, staffing problems

8 AFR Measles-Rubella TAG Meeting, 2015 8 |8 | Workload at Laboratory 2014: Drop in number of specimens received at NLs in WA & in number of specimens received at IPCIV RRL (Impact of EVD outbreak) Increase in number of specimens received at NICD RRL (re establishment of testing)

9 AFR Measles-Rubella TAG Meeting, 2015 9 |9 | Workload at Laboratory (cn’t)  Few shipments performed by NLs in 2014 vs 2013  No shipment performed by some labs  Refusal from DHL carrier to organize shipment of blood specimen due to on going EVD outbreak in WA

10 AFR Measles-Rubella TAG Meeting, 2015 10 | Quality of Specimens Specimens received in good condition in most of the case. 90% minimum target met except for specimen received at NICD lab in 2014)

11 AFR Measles-Rubella TAG Meeting, 2015 11 | Measles IgM Suspected case of measles Blood specimen IgM(-/+) IgM(+) IgM(-) Rubella IgM Repeat Measles IgM Measles IgM (+/-) Measles IgM (+) Rubella IgM (-) Rubella IgM (+) Rubella IgM (-/+) Measles IgM (-) Lab. Testing Algorithm

12 AFR Measles-Rubella TAG Meeting, 2015 12 | Lab. Testing Algorithm (cn’t) Some labs do not strictly follow algorithm & run simultaneous measles & rubella IgM test to save times

13 AFR Measles-Rubella TAG Meeting, 2015 13 | Timeliness in sending out IgM results to EPI/surveillance WA below the 80% expected target in 2013 & 2014 due to shortage of kits (NIE impact)- Long term shortage of kits in 2014 (funding issues) affected most labs

14 AFR Measles-Rubella TAG Meeting, 2015 14 | Timeliness in sending out IgM results to EPI/surveillance National Laboratory IST WA, 2004 Timeliness (%) in sharing IgM results Shortage of measles/rubella kits Country affected by EVD outbreak ALG 31 BEN 69 BFA 100 CIV 95 GAM 50 GHA 94 GUI 64 MAI 76 MAU 70 NIE-CPHL 20 NIE-FCT 97 NIE-SGH 54 NIE-YDMH 25 NIG 88 SEN 32 SIL 0 TOG 59

15 AFR Measles-Rubella TAG Meeting, 2015 15 | Timeliness in sending back IgM Results to NLs  Expected target not met -By IPCIV RRL in 2013 & 2014 -By NICD RRL in 2014  IPCIV= RRL for 27 NLs. High number of specimens usually received (incl. from Nigeria)  Shortage of kits has affected this indicator for IPCIV

16 AFR Measles-Rubella TAG Meeting, 2015 16 |  High number of kits purchased in 2014 (twice more) than 20013  Increasing needs from labs. Reason: outbreak ???  Unit price for Siemens IgM kit: Measle & rubella (295 Euros each), Supplementary (39 Euros)  Total cost (excluding transport ) -2013: 172 264 Euros -2014: 337 592 Euros Supply of Kits

17 AFR Measles-Rubella TAG Meeting, 2015 17 | Proficiency Test & Accreditation status Excellent performance obtained for annual Proficiency Test except 1 lab (not accredited) - Sub optimal documentation & implementation of internal quality control procedures (provisionally accredited),

18 AFR Measles-Rubella TAG Meeting, 2015 18 | D10 B2 B3 D4 D2 Measles Genotype Identified: 2005-2014  Identified from specimen collected from outbreak & QC  Sequencing performed lab: NICD,UVRI & CDC  IPCIV: sequencing started in 2015  B3 largely circulating (In 2014 identified in ZIM,NIE & TOG)

19 AFR Measles-Rubella TAG Meeting, 2015 19 | Main Challenges  Suboptimal weekly reporting timeliness/completeness – Internet connectivity problems – Competing laboratory activities  High staff turn over in some labs (ETH, MAL, South Sudan)  Inconsistency in management of lab reagent – Stock outs ok kit due to outbreaks – Inaccuracy in estimating the needs & supply of kits with short expiring date  Insufficient/inadequate coordination between lab & surveillance – Continuous collection of blood specimen during measles outbreaks – Missed opportunity to collect specimen for virus isolation/genotyping

20 AFR Measles-Rubella TAG Meeting, 2015 20 | Main Challenges (cn’t)  Limited funding to cover lab activities (heavily dependant on WHO) – To purchase kits & sequencing reagents/supplies – To organize trainings  Effect of EVD outbreak -Shipment of QC specimen stopped in several countries, -2014 lab director meeting cancelled

21 AFR Measles-Rubella TAG Meeting, 2015 21 | Way Forward  Integration of additional measles lab: SEY, Mauritius (countries on elimination mode)  Full implementation of sequencing activities at IPCIV RRL  Strengthen collaboration between lab & surveillance  Secure alternative carriers to transport specimens for QC  Reconvene annual lab director meeting  Advocate for additional funding for the lab network - Explore Nigeria willingness to purchase kits

22 AFR Measles-Rubella TAG Meeting, 2015 22 | How can we advocate /mobilize more funds to cover measles laboratory network needs??? Question For MR TAG Members

Download ppt "AFR Measles-Rubella TAG Meeting, 2015 1 |1 | The Performance of the Regional Laboratory Network Nairobi, 2-3 June 2015 The Performance of the Regional."

Similar presentations

Global Measles and Rubella Strategic Plan

Global Measles and Rubella Strategic Plan
Nursing and Lab partnering to perform

Nursing and Lab partnering to perform
ORGANIZATION. 2 Problem scenario  Develop an organizational chart for your laboratory showing lines of authority from the head of the organization to.

ORGANIZATION. 2 Problem scenario  Develop an organizational chart for your laboratory showing lines of authority from the head of the organization to.
A global partnership to stop measles & rubella Competent and Sustainable Global Laboratory Surveillance for Measles and Rubella is Provided by the WHO.

A global partnership to stop measles & rubella Competent and Sustainable Global Laboratory Surveillance for Measles and Rubella is Provided by the WHO.
Monitoring progress towards the coverage and disease incidence targets GLOBAL MEASLES AND RUBELLA MANAGEMENT MEETING 15-17 March 2011 Geneva, Switzerland.

Monitoring progress towards the coverage and disease incidence targets GLOBAL MEASLES AND RUBELLA MANAGEMENT MEETING March 2011 Geneva, Switzerland.
Measles and Rubella Elimination in the WHO European Region: Update on Progress & Challenges Global Measles and Rubella Management Meeting 15-17 March 2011.

Measles and Rubella Elimination in the WHO European Region: Update on Progress & Challenges Global Measles and Rubella Management Meeting March 2011.
This teaching material has been made freely available by the KEMRI-Wellcome Trust (Kilifi, Kenya). You can freely download, adapt, and distribute this.

This teaching material has been made freely available by the KEMRI-Wellcome Trust (Kilifi, Kenya). You can freely download, adapt, and distribute this.
A global partnership to stop measles & rubella The Measles & Rubella Initiative: Preparing for the Next Decade Lisa Cairns, MD, MPH Sept 18, 2012 Washington,

A global partnership to stop measles & rubella The Measles & Rubella Initiative: Preparing for the Next Decade Lisa Cairns, MD, MPH Sept 18, 2012 Washington,
Measles control and elimination in the Eastern Mediterranean Region

Measles control and elimination in the Eastern Mediterranean Region
1. 2 The Public Health Agency of Canada Pandemic Influenza Preparedness: An Overview Dr. Paul Gully Deputy Chief Public Health Officer Ottawa, 19 January.

1. 2 The Public Health Agency of Canada Pandemic Influenza Preparedness: An Overview Dr. Paul Gully Deputy Chief Public Health Officer Ottawa, 19 January.
Managing the Information Technology Resource Jerry N. Luftman

Managing the Information Technology Resource Jerry N. Luftman
This teaching material has been made freely available by the KEMRI-Wellcome Trust (Kilifi, Kenya). You can freely download, adapt, and distribute this.

This teaching material has been made freely available by the KEMRI-Wellcome Trust (Kilifi, Kenya). You can freely download, adapt, and distribute this.
1 Module PLANNING AND ORGANIZING EXTERNAL QUALITY ASSESSMENT.

1 Module PLANNING AND ORGANIZING EXTERNAL QUALITY ASSESSMENT.
Proceedings of the SAGE Working Group on Rubella Vaccines Susan E. Reef, MD Global Measles and Rubella Management Meeting March 15, 2011.

Proceedings of the SAGE Working Group on Rubella Vaccines Susan E. Reef, MD Global Measles and Rubella Management Meeting March 15, 2011.
Building EID Programs Highlights –Bulk purchase of PCR kits reduces cost – now at around 8 USD per test –Supplying DNA PCR tests – with bundles for DBS.

Building EID Programs Highlights –Bulk purchase of PCR kits reduces cost – now at around 8 USD per test –Supplying DNA PCR tests – with bundles for DBS.
Global Measles and Rubella Management Meeting Progress and Challenges in Bangladesh 15-17 March, 2011 Geneva, WHO HQ Dr Serguei Diorditsa.

Global Measles and Rubella Management Meeting Progress and Challenges in Bangladesh March, 2011 Geneva, WHO HQ Dr Serguei Diorditsa.
Invalid MCV1 doses – how big a problem? B Masresha WHO AFRO AFR MR TAG Meeting Nairobi, June 2015.

Invalid MCV1 doses – how big a problem? B Masresha WHO AFRO AFR MR TAG Meeting Nairobi, June 2015.
© 2003 IBM Corporation July 2004 Technology planning for not-for-profit organizations IBM volunteer name Title, organization.

© 2003 IBM Corporation July 2004 Technology planning for not-for-profit organizations IBM volunteer name Title, organization.
Measles Initiative Financing 2001-2008 February 28, 2007 Washington, D.C. Andrea Gay UN Foundation for Measles Partners.

Measles Initiative Financing February 28, 2007 Washington, D.C. Andrea Gay UN Foundation for Measles Partners.
1 Accreditation and Certification: Definition  Certification: Procedures by which a third party gives written assurance that a product, process or service.

1 Accreditation and Certification: Definition  Certification: Procedures by which a third party gives written assurance that a product, process or service.

Similar presentations

Ads by Google